Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy

Yicong Chen; Huijiao Chen; Ruixuan Yu; Xiaoxiao Zeng; Dong Tian; Qiang Pu; Yongmei Liu

doi:10.1016/j.lungcan.2024.107476

Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy

Lung Cancer. 2024 Mar:189:107476. doi: 10.1016/j.lungcan.2024.107476. Epub 2024 Jan 24.

Authors

Yicong Chen¹, Huijiao Chen², Ruixuan Yu¹, Xiaoxiao Zeng³, Dong Tian⁴, Qiang Pu⁴, Yongmei Liu⁵

Affiliations

¹ Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
² Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
³ Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Department of Oncology, The People's Hospital of Jianyang City, Jianyang, Sichuan 641400, China.
⁴ Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
⁵ Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. Electronic address: lymi75@163.com.

PMID: 38280290
DOI: 10.1016/j.lungcan.2024.107476

Abstract

Pulmonary blastomas (PB) are an extremely rare type of lung cancer. Currently, no standard treatment exists for PB. Immunotherapy with checkpoint inhibitors and anti-angiogenesis treatments has been an effective method for lung cancer; however, studies on PB treatment are lacking. Herein, we present a case report of successful conversion therapy with immunotherapy and targeted therapy for PB. After receiving treatment with a PD-1 inhibitor (penpulimab) and a multi-target tyrosine kinase inhibitor (anlotinib) treatment, the patient showed an impressive response and underwent a successful operation. We also summarized and reviewed literature reports on PubMed from January 1, 2000, to December 31, 2022, using the keyword "pulmonary blastoma", discussing the efficacy and specifics of chemotherapy and radiotherapy. Immunotherapy, in combination with targeted therapy, should be considered a potential therapeutic strategy for PB.

Keywords: Combination therapy; Immunotherapy; Pulmonary blastoma; Targeted therapy.

Publication types

Case Reports
Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immune Checkpoint Inhibitors
Immunotherapy
Lung Neoplasms* / therapy
Protein Kinase Inhibitors / therapeutic use
Pulmonary Blastoma* / therapy

Substances

Immune Checkpoint Inhibitors
Protein Kinase Inhibitors